Values First Advisors Inc. Sells 929 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Values First Advisors Inc. lessened its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 5.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,195 shares of the company’s stock after selling 929 shares during the period. Values First Advisors Inc.’s holdings in Aura Biosciences were worth $153,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AURA. Long Focus Capital Management LLC lifted its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares during the period. Regency Capital Management Inc. DE increased its stake in shares of Aura Biosciences by 11.4% during the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after purchasing an additional 80,162 shares in the last quarter. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 194.5% during the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after buying an additional 48,549 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $10.92 on Friday. The company has a market capitalization of $541.01 million, a price-to-earnings ratio of -5.87 and a beta of 0.37. The stock has a 50-day moving average of $8.99 and a 200 day moving average of $8.20. Aura Biosciences, Inc. has a one year low of $5.99 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.04. On average, equities analysts predict that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the transaction, the chief financial officer now owns 134,276 shares of the company’s stock, valued at approximately $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,506 shares of company stock valued at $675,952 in the last ninety days. 5.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on AURA shares. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. HC Wainwright increased their price objective on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Finally, Cowen reiterated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.